HC Wainwright Has Bullish Estimate for RYTM Q1 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for Rhythm Pharmaceuticals in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.68) per share for the quarter, up from their previous estimate of ($0.81). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.72) EPS and FY2025 earnings at ($2.79) EPS.

A number of other brokerages also recently weighed in on RYTM. Stifel Nicolaus initiated coverage on shares of Rhythm Pharmaceuticals in a report on Wednesday. They set a “buy” rating and a $78.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Thursday, February 27th. The Goldman Sachs Group raised their target price on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Jefferies Financial Group began coverage on Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They set a “buy” rating and a $80.00 price target on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $69.31.

Rhythm Pharmaceuticals Stock Down 1.6 %

RYTM stock opened at $50.79 on Thursday. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -11.73 and a beta of 2.30. Rhythm Pharmaceuticals has a twelve month low of $35.17 and a twelve month high of $68.58. The business has a 50 day moving average price of $56.63 and a two-hundred day moving average price of $54.45.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million during the quarter, compared to the consensus estimate of $38.48 million.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Castleark Management LLC increased its holdings in Rhythm Pharmaceuticals by 1.3% in the 3rd quarter. Castleark Management LLC now owns 19,260 shares of the company’s stock valued at $1,009,000 after buying an additional 250 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Rhythm Pharmaceuticals by 2.3% during the 4th quarter. Two Sigma Advisers LP now owns 13,100 shares of the company’s stock worth $733,000 after buying an additional 300 shares in the last quarter. SRS Capital Advisors Inc. lifted its position in shares of Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after buying an additional 400 shares during the last quarter. Raleigh Capital Management Inc. acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at about $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Rhythm Pharmaceuticals by 2.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,156 shares of the company’s stock valued at $1,857,000 after acquiring an additional 654 shares during the last quarter.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CEO David P. Meeker sold 9,896 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total transaction of $566,249.12. Following the transaction, the chief executive officer now owns 201,281 shares in the company, valued at $11,517,298.82. This trade represents a 4.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the transaction, the chief accounting officer now directly owns 2,070 shares of the company’s stock, valued at $118,445.40. This represents a 23.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,787 shares of company stock valued at $1,901,443. 5.60% of the stock is currently owned by corporate insiders.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.